Insulin-like Growth Factor-I-stimulated Insulin Receptor Substrate-1 Negatively Regulates Src Homology 2 Domain-containing Protein-tyrosine Phosphatase Substrate-1 Function in Vascular Smooth Muscle Cells by Radhakrishnan, Yashwanth et al.
Insulin-like Growth Factor-I-stimulated Insulin Receptor
Substrate-1 Negatively Regulates Src Homology 2
Domain-containing Protein-tyrosine Phosphatase
Substrate-1 Function in Vascular Smooth Muscle Cells*□S
Received for publication, December 5, 2009, and in revised form, March 2, 2010 Published, JBC Papers in Press, March 5, 2010, DOI 10.1074/jbc.M109.092270
Yashwanth Radhakrishnan, Walker H. Busby, Jr., Xinchun Shen, Laura A. Maile, and David R. Clemmons1
From the Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599
Vascular smooth muscle cells maintained in normal (5.6 mM)
glucose respond to insulin-like growth factor-I (IGF-I) with
increased protein synthesis but do not proliferate. In contrast,
hyperglycemia alters responsiveness to IGF-I, resulting in
increased SHPS-1 phosphorylation and assembly of a signaling
complex that enhances MAPK and phosphatidylinositol 3-ki-
nase pathways. Hyperglycemia also reduces the basal IRS-1 con-
centration and IGF-I-stimulated IRS-1-linked signaling. To
determine if failure to down-regulate IRS-1 alters vascular
smooth muscle cell (VSMC) responses to IGF-I, we overex-
pressed IRS-1 in VSMCsmaintained in high glucose. These cul-
tures showed reduced SHPS-1 phosphorylation, transfer of
SHP-2 to SHPS-1, and impaired Shc and MAPK phosphoryla-
tion and cell proliferation in response to IGF-I. In vitro studies
demonstrated that SHPS-1 was a substrate for type I IGF recep-
tor (IGF-IR) and that IRS-1 competitively inhibited SHPS-1
phosphorylation. Exposure of VSMC cultures to a peptide that
inhibited IRS-1/IGF-IR interaction showed that IRS-1 binding
to IGF-IR impairs SHPS-1 phosphorylation in vivo. IRS-1 also
sequestered SHP-2. Expression of an IRS-1 mutant (Y1179F/
Y1229F) reduced IRS-1/SHP-2 association, and exposure of
cells expressing the mutant to the inhibitory peptide enhanced
SHPS-1 phosphorylation and SHP-2 transfer. This result was
confirmed by expressing an IRS-1 mutant that had both
impaired binding to IGF-IR and to SHP-2 IGF-I increased
SHPS-1 phosphorylation, SHP-2 association with SHPS-1, Shc
MAPK phosphorylation, and proliferation in cells expressing the
mutant. We conclude that IRS-1 is an important factor for main-
taining VSMCs in the non-proliferative state and that its down-
regulation is a componentof theVSMCresponse tohyperglycemic
stress that results in an enhanced response to IGF-I.
Insulin-like growth factor-I (IGF-I)2 binds selectively to the
type I IGF receptor, which results in stimulation of several bio-
logical functions. IGF-I is a known stimulant of vascular
smooth muscle cell (VSMC) proliferation and migration, and
these effects are mediated through the phosphatidylinositol
3-kinase and MAPK pathways (1–3). Upon ligand occupancy,
the receptor undergoes a conformational change that activates
its tyrosine kinase, which phosphorylates downstream signal-
ing molecules. IRS-1 (insulin receptor substrate-1) is one of the
important substrates for both the insulin and IGF-I receptor
tyrosine kinases (4, 5). IRS-1 is a docking protein that contains
multiple domains that mediate protein-protein interactions,
including a pleckstrin homology domain, a phosphotyrosine-
binding (PTB) domain, and the carboxyl terminus (5, 6). The
PTB domain binds directly to the phosphorylated NPXY motif
located within the activated insulin, IGF-I, or interleukin-4
receptors (7–10). In addition, the pleckstrin homology domain
also couples IRS-1 to activated receptors (11). The carboxyl
terminus of IRS-1 contains several phosphotyrosines that
interact with Src homology 2 domains of signaling mole-
cules. Following their phosphorylation, several signaling
intermediates, such as Grb-2, p85, and SHP-2 (Src homology
2 domain-containing protein-tyrosine phosphatase 2), bind
to IRS-1, leading to activation of downstream signaling
events (12, 13). IRS-1 has been linked to many of the insulin-
or IGF-I-mediated biological responses, including changes
in cell size, mitogenesis, and cell migration (14–16). IGF-I-
stimulated IGF-IR has been shown to bind to IRS-1 and
phosphorylate it in several cell types, including vascular
smooth muscle cells (17, 18).
Previous studies have shown that the trans-membrane scaf-
folding protein SHPS-1 (SHP substrate-1) is a substrate for acti-
vated tyrosine kinases (19). Our studies have shown that
SHPS-1 phosphorylation and the subsequent assembly of a sig-
naling complex that includes SHP-2, Src, Shc (Src homology 2
domain-containing protein), and Grb2 (growth factor recep-
tor-bound protein 2) is essential for these cells to respond to
hyperglycemic stress and that it enhances the ability of IGF-I to
activate both MAPK and phosphatidylinositol 3-kinase path-
ways, leading to increased proliferation andmigration (2, 3, 20).
Following their tyrosine phosphorylation, IRS-1 and Shc bind
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independently to Grb2, which increases activation of MAPK/
extracellular signal-regulated kinase (ERK) (2, 21, 22). How-
ever, the relative contribution of Shc and IRS-1 in regulating
this cascade has not been clearly delineated for many different
cell types (12, 23). Additionally, IRS-1 concentrations are regu-
lated by several factors, including glucose, insulin, IGF-I, and
cell/tissue type (24–30). Several investigators have demon-
strated that IRS-1 concentrations are down-regulated in
response to hyperglycemia in insulin-sensitive tissues as skele-
tal muscle and fat (13, 31, 32). Previously, we reported that
VSMCs maintained in high glucose concentrations (12 mM)
had a significant decrease in IRS-1. We also showed that the
IRS-1 tyrosine phosphorylation response and subsequent Grb2
binding are significantly reduced in response to IGF-I (29).
These studies were undertaken to determine the significance of
the reduction in IRS-1 and whether failure to reduce the IRS-1
concentration alters assembly of the SHPS-1 complex, thus
leading to altered cell proliferation andmigration in response to
IGF-I.
MATERIALS AND METHODS
Human IGF-I was a gift from Genentech (South San Fran-
cisco, CA). Immobilon-P membranes were purchased from
Millipore Corp. (Bedford,MA). DMEMcontaining 4500mg/li-
ter glucose (DMEM-HG), DMEM containing 900 mg/liter glu-
cose (DMEM-NG), and streptomycin and penicillin were pur-
chased from Invitrogen. Antibodies against phospho-MAPK or
total MAPK and -actin were purchased from Cell Signaling
(Beverly, MA). Polyclonal antibodies for IRS-1, SHPS-1, and
Shc were obtained from Upstate Biotechnology (Lake Placid,
NY). Anti-phosphotyrosine (Tyr(P)99), the hemagglutinin
epitope (HA), anti-IRS-1, anti-IGF-IR, anti-SHP-2, and anti-
Grb2 antibodies were purchased from Santa Cruz Biotechnol-
ogy, Inc. (Santa Cruz, CA). SHPS-1 and IGF-IR polyclonal anti-
serum were prepared in our laboratory. IGF-IR tyrosine kinase
inhibitor, PQ401, was purchased fromTocris Bioscience, (Ellis-
ville, MO). Recombinant rat IRS-1 expressed in Sf9 cells with
His tag was purchased from Millipore Corp. Synthetic pep-
tides containing the cell permeability sequence of protein
transduction domain 4 and the sequence from IGF-IR YARA-
AARQARA947NPEYFSAADV956 (underlined and hereafter
referred to as peptide 299), the tyrosine-phosphorylated form
of p299 peptide (corresponding to Tyr950 of IGF-IR), and
the sequence from the IRS-1 PTB domain YARAAA-
RQARA206LQLMNIRRCGHS217 (underlined and hereafter
referred to as peptide 301, whereC is italicized to denote reduc-
tion) were synthesized by the Protein Chemistry Core Facility
at the University of North Carolina at Chapel Hill. Purity and
sequence confirmation were determined by mass spectro-
metry. We used a heterologous system in this study. It is
important to note that the sequences in porcine IGF-IR that
bind to IRS-1 are conserved in human IGF-IR. Likewise, the
IGF-I receptor tyrosine kinase sequence is completely con-
served when human and porcine IGF-IR are compared. Sim-
ilarly, the PTB domain of porcine IRS-1 has 100% homology
to human IRS-1. Finally, porcine IGF-I and human IGF-I
have 100% sequence identity. Therefore, we believe that this
degree of sequence conservation enables us to study these
interactions interchangeably.
Construction, Expression, and Purification of the Cytoplasmic
Domain of SHPS-1 (SHPS-1/CD) and IGF-IR—The SHPS-1
cytoplasmic domain containing amino acids 394–503 was
PCR-amplified with the SP6 promotor sequence, following
which reverse transcription was performed to obtain mRNA
(33). Using this template, SHPS-1/CD was generated, employ-
ing in vitro translation using wheat germ extract as per the
manufacturer’s recommendation (Promega).
The mouse fibroblasts (NWTb3) that overexpress human
IGF-IR were a kind gift from Dr. Derek LeRoith (Mount Sinai
School of Medicine, New York) (34). IGF-IR was purified using
NWTb3 cell lysate (25ml of cell lysis buffer (50mMHEPES, pH
7.5, 150 mM NaCl containing protease inhibitors aprotinin (10
g/ml), leupeptin (1 g/ml), 4-(2-aminoethyl)-benzenesulfo-
nyl fluoride (1 mM), pepstatin (1 g/ml), EDTA (2 mM), and
Triton X-100 (0.2%)) diluted 1:5 with buffer containing (50 mM
HEPES, pH7.5, 1M ammoniumsulfate, 1mM4-(2-aminoethyl)-
benzenesulfonyl fluoride, 2mMEDTA, 1g/ml pepstatin, and 1
g/ml leupeptin). The diluted lysate was applied to a butyl-
Sepharose column previously equilibrated with 50 mM HEPES,
pH 7.5, containing 1 M ammonium sulfate and 0.02% Triton
X-100. After sample loading, the column was washed with
equilibration buffer and eluted with 25 mM HEPES, pH 7.5,
containing 0.02% Triton X-100. Fractions containing IGF-IR
were detected following SDS-PAGEwith immunoblotting. The
fractions containing the receptor were further purified using
concanavalinA chromatography. CaCl2 andMnCl2were added
to final concentrations of 4 and 2 mM, respectively, and the
solution was applied to a concanavalin A-Sepharose column,
equilibrated with 50 mM Tris, pH 7.2, 0.4 mM CaCl2, 2 mM
MnCl2, and 0.02% Triton X-100. The IGF-IR was eluted with
the above buffer containing 0.25Mmethyl-D-glucopyranoside
and 0.25 M methyl -D-mannopyranoside.
IGF-IR and SHPS-1 Phosphorylation Measurement—The
purified IGF-IR was incubated with 150 ng/ml IGF-I and 10
mM ATP in a buffer containing 50 mM HEPES-NaOH (pH
7.6), 3 mM MnCl2, 10 mM MgCl2, 0.1 mM EGTA, and 0.1 mM
Na3O4 and incubated for 15 min for 30 min. IGF-IR activa-
tion was determined by immunoblotting using anti-Tyr(P)99
antibody. The activated IGF-IR was used to phosphorylate
the cytoplasmic domain of SHPS-1 in a buffer containing 50
mM HEPES-NaOH (pH 7.6), 3 mM MnCl2, 10 mM MgCl2, 0.1
mM EGTA, 1 mM dithiothreitol, 0.1 mM Na3O4, and 0.2 mM
ATP and incubation at 30 °C for 30 min. To determine phos-
phorylation of SHPS-1/CD, the final product was immuno-
blotted using an anti-Tyr(P)99 antibody.
Cell Culture—Porcine SMCs were isolated from the por-
cine aortic explants according to the protocol described by
Ross (74) and were maintained as described previously (2,
29). Cells were maintained in DMEM-high glucose growth
medium (HG) or DMEM-normal glucose growth medium
(NG) with 10% fetal bovine serum (Hyclone, Logan, UT),
streptomycin (100 ng/ml), and penicillin (100 units/ml). All
of the mutant cells were maintained in HG. The SMCs that
were used in these experiments were used between passages
4 and 12.
IGF-I-induced IRS-1 Impairs SHPS-1 Function
MAY 21, 2010 • VOLUME 285 • NUMBER 21 JOURNAL OF BIOLOGICAL CHEMISTRY 15683
Generation of pLenti Expression Vectors pLenti-HA-IGF-IR
Wild Type, pLenti-HA-IRS-1 wild type (IRS-1-WT), pLenti-HA-
IRS-1-FF mutant (IRS-FF), and pLenti-HA- IRS-1-R3Q-FF
Double Mutant (IRS-R3Q-FF)—Wild type IGF-IR in pBlue-
script II KSwas a kind gift fromDr.Derek LeRoith. Using this as
a template, PCR amplification was performed with forward
primer 5-caccatgaagtctggctccggaggagggt-3, including a
Kozak sequence (in boldface type) placed 5 to theATG (under-
lined) start site. The reverse primer 5-ttaagcgtaatctggaacatcg-
tatgggtagcaggtcgaagactggggcagcgg-3 contained the sequence
encoding HA epitope (underlined), followed by the stop codon
(boldface type). The amplified product was cloned into the
pENTR/D-TOPOGateway entry vector according to the man-
ufacturer’s instructions (Invitrogen). The resultant productwas
confirmed by sequencing (University of North Carolina
Genome Analysis Facility, Chapel Hill, NC) and transferred
from the entry vector into the pLentiCMV DEST vector using
the LR clonase reaction following the manufacturer’s instruc-
tions (Invitrogen). Full-length human IRS-1 cDNA was pur-
chased from Open Biosystems in pCMV-sport6 vector and
after PCR amplification was cloned into the pENTR/D-TOPO
Gateway entry vector according to the manufacturer’s instruc-
tions (Invitrogen). The forward and reverse primers used to
generate the PCR product were as follows: forward primer,
5-caccatggcgagccctccggagagcgat-3; reverse primer, 5-tta-
agcgtaatctggaacatcgtatgggtactgacggtcctctggctgcttctgg-3. The
forward primer includes a Kozak sequence (boldface type)
placed 5 to theATG (underlined) start site. The reverse primer
contained the sequence encoding HA epitope (underlined) fol-
lowed by the stop codon (boldface type). The resultant product
was sequenced (UNC Genome Analysis Facility, Chapel Hill,
NC) to confirm the correct full-length human IRS-1 usingM13
forward and reverse primers and five other primers: IRS-
1Seq1A, 5-gggtcagacaaagaacctgatt-3; IRS-1Seq2A, 5-cgc-
ccagcctcggtgga-3; IRS-1Seq3A, 5-ctaccattacccaccagaag-3;
IRS-1Seq4A, 5-tgactacatgaacatgtcacca-3; IRS-1Seq5C, 5-tga-
ccatgcagatgagttgtcc-3.
Using the pENTR IRS-1-WT as template, an IRSmutant was
generated where the tyrosines at positions 1179 and 1229 were
mutated to phenylalanine (IRS-FF). PCR amplifications were
carried out using complementary primer 5-ggagaatggtcttaact-
Tcatagacctggatttgg-3 and reverse primer 5-ccaaatccaggtctat-
gAagttaagaccattctcc-3 to generate Y1179F and another com-
plementary primer 5-gaggatttaagcgcctTtgccagcatcag-3 and
reverse primer 5-ctgatgctggcaAaggcgcttaaatcctc-3 to gener-
ate Y1229F (where capitalized bases indicate the substitutions).
After selection of correct clone based on DNA sequencing,
using pENTR IRS-FF as template, a double mutant was con-
structed where three arginines at positions 212, 213, and 227
were mutated to glutamine (IRS-R3Q-FF) using double-
stranded mutagenesis. Initially, PCR amplification was carried
out using forward primer 5-gctgatgaacatcCAgcAAtgtggc-
cactcgg-3 and reverse primer 5-ccgagtggccacaTTgcTGgatgt-
tcatcagc-3 (where capitalized bases indicate the substitutions),
by which two of the residues, Arg212 and Arg213, were mutated
to glutamine. The resultant DNA was used as a template, and
the arginine at position 227 was mutated to glutamine using
complementary primers 5-catcgaggtgggccAAtctgccgtgac-
gggg-3 and reverse primer 5-ccccgtcacggcagaTTggcccacctc-
gatg-3 (where capitalized bases indicate the substitution). The
products were sequenced (University of North Carolina
GenomeAnalysis Facility) to confirm the correct incorporation
of the changes, following which the cDNAs encoding the wild
type, single mutant, and double mutant forms of the protein
were transferred from the entry vector into pLentiCMV DEST
vector using the LR clonase reaction following themanufactur-
er’s instructions (Invitrogen).
Construction of a Plasmid Containing Short Hairpin RNA
Template for IRS-1 Silencing—Based on Invitrogen web site
design tools, a sequence containing 21 oligonucleotides
(GCGAGGATTTAAGCGCCTATG) located within the por-
cine IRS-1 (accession number EU681268.1; nucleotides 3515–
3536) was used to construct the short hairpin RNA template
plasmid. The selected sequences were not found in any other
mammalian protein searched using the NCBI Blast search pro-
gram. The oligonucleotides were synthesized by the Nucleic
Acids Core Facility at the University of North Carolina,
annealed, and ligated into BLOCK-iT U6 RNAi entry vector
(catalogue no. K4945-00, Invitrogen), following the manufac-
turer’s instructions. The complete sequence was verified by
DNA sequencing. The expression vector was generated using
theGateway LR recombination reaction between the entry vec-
tor and BLOCK-iT Lentiviral RNAi Gateway Vector (catalogue
no. K4943-00, Invitrogen). The empty vector was used as a con-
trol (EVC). After confirmation of the sequence, plasmid DNA
was prepared by a Plasmid minikit (Promega, Madison, WI).
Generation of Virus Stocks—293FT cells (Invitrogen) were
prepared for generation of virus stocks of each individual
pLenti construct. All of the transfections and viral stock gener-
ations were carried out as described previously (2, 3).
Establishment of Porcine VSMCs Expressing pLenti
Constructs—VSMCs (passages 4 and 5) were seeded at 3 105/
well in each of two wells of a 6-well plate (catalog no. 353046,
Falcon) the day before transduction. The viral stocks were
thawed, and the viral complexes were precipitated as described
previously (2, 3). The expression of the HA-tagged IRS-1-WT
and IRS-1 mutants were detected by immunoblotting with a
1:1000 dilution of anti-HA antibody using 20 g of protein.
Immunoprecipitation and Immunoblotting—Cells were
seeded at 5 105 cells/10-cmplate (BDBiosciences) and grown
for 5–7 days to reach confluence. The cultures were incubated
in serum-free DMEM-HG for 14–18 h before the addition of
IGF-I (as indicated). In some experiments, non-transduced
SMCs were preincubated with or without the synthetic pep-
tides for 1–2 h before IGF-I was added. Following cell lysis, all
immunoprecipitations and immunoblottingwere carried out as
described previously (2, 3). The proteins were detected using
enhanced chemiluminescence (Pierce). The images obtained
were also scanned using DuoScan scanning densitometer
(Agfa, Morstel, Belgium). Densitometric analyses of the images
were determined using National Institutes of Health ImageJ,
version 1.37v. To determine differences in MAPK phosphory-
lation, arbitrary scanning units obtained for phospho-MAPK
band intensities were divided by arbitrary scanning units
obtained for total-actin protein band intensities for each time
point analyzed. The -fold values or average ratio values
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obtained from at least three independent experiments for each
lane were pooled together.
Cell Proliferation Assay and Wounding and Migration
Assay—Assessment of SMC proliferation was performed as
described previously (35). IGF-I is known to stimulate smooth
muscle cell chemokinesis, and cellular migration was analyzed
as previously described (36). Briefly, VSMCs were plated in
6-well dishes and grown to confluence. The monolayer of cells
was wounded with a razor blade.
After wounding, cells were incu-
batedwith SFMplus 0.2% FBS in the
presence or absence of IGF-I (50
ng/ml) at 37 °C for 48 h. The
wounded monolayers were then
fixed and stained (Diff Quick; Dade
Behring, Inc., Newark, DE), and the
number of cells migrating into the
wound area was counted. At least
five of the previously selected 1-mm
areas at the edge of the wound were
counted for each data point.
Statistical Analysis—Student’s t
test was used to compare the differ-
ences between the treatments. The
results that are shown in all experi-
ments are representative of at least
three separate experiments, and p
0.05 was considered statistically
significant.
RESULTS
Effect of Glucose and IGF-I on
Total IRS-1 Protein Levels and IRS-1
Signaling—VSMCs that were main-
tained in 25 mM glucose (DMEM-
HG) and then changed to serum-
free medium containing the same
glucose concentration for 12 h had a
significant decrease in total IRS-1
levels (1.8  0.1-fold, n  3, p 
0.01) compared with cells that were
exposed to 5 mM glucose (DMEM-
NG). The degree of decrease in
IRS-1 was maintained after 24 h
(1.9  0.1-fold, n  3, p  0.01) and
48 h (2.4 0.2-fold, n 3, p 0.01)
(Fig. 1A, top). Similar cultures stim-
ulated with IGF-I for 24 and 48 h
showed a significant additional
decrease (1.9  0.1-fold at 24 h
and 1.7  0.2-fold at 48 h, n  3,
p  0.01) in total IRS-1 in
DMEM-HG compared with
VSMCs not exposed to IGF-I (Fig.
1A, middle). Consistent with our
previous observations, tyrosine
phosphorylation of IRS-1 (cor-
rected for changes in total IRS-1)
in response to IGF-I was significantly reduced (4.2  0.3-
fold, n  5, p  0.001) in DMEM-HG cells compared with
DMEM-NG cells (Fig. 1B). Grb2 association with IRS-1 was
significantly decreased (8.1  0.1-fold, n  5, p  0.001) in
DMEM-HG cells compared with DMEM-NG cultured cells
in response to IGF-I (Fig. 1B).
In order to determine the effect of maintaining a higher level
of IRS-1 thanwould normally be present in hyperglycemic con-
FIGURE 1. Hyperglycemia decreases total IRS-1 protein levels and IRS-1-mediated signaling. A, confluent
VSMC cultures were maintained in medium containing 5 mM (NG) or 25 mM (HG) glucose prior to these analy-
ses. They were changed to serum-free medium containing the same glucose concentration for 12, 24, or 48 h
without (top) or with (second panel) IGF-I (50 ng/ml). The anti--actin antibody (loading control) is shown in the
lower panel. After cell lysis, aliquots containing equal amounts of protein were separated directly by SDS-PAGE
and immunoblotted (IB) with anti-IRS-1 antibody. The bar graph is representative of three independent exper-
iments without IGF-I. Error bars, mean  S.E. **, p  0.01. B, the extent of IRS-1 tyrosine phosphorylation was
determined by immunoprecipitating (IP) cell lysates with an anti-IRS-1 antibody and then immunoblotting
with an anti-Tyr(P)99 (PY99) antibody (first panel), and Grb-2 association with IRS-1 was determined by immu-
noprecipitating with an anti-Grb2 antibody and then immunoblotting with anti-IRS-1 antibody (third panel).
The membranes were stripped and reprobed with either anti-IRS-1 or anti-Grb2 antibody to detect the total
levels of IRS-1 (second panel) or Grb2 (fourth panel), respectively. The amount of immunoprecipitate analyzed
was adjusted to correct for differences in total IRS-1 between the NG and HG cultures. The bar graph represents
three independent experiments. Error bars, mean  S.E. ***, p  0.001 when the amount of tyrosine phosphor-
ylation of IRS-1 or the amount of Grb2 associated with IRS-1 at 5 min in response to IGF-I is compared between
NG and HG cultures. C, VSMCs expressing either LacZ or IRS-WT were serum-starved in DMEM-HG and analyzed
for recombinant protein expression. Cell lysates were immunoblotted using an anti-HA antibody (top), anti-
IRS-1 antibody (middle), and an anti--actin antibody loading control (bottom). D, confluent VSMCs expressing
LacZ or IRS-WT cultured in HG were serum-deprived and stimulated without or with IGF-I (50 ng/ml) for 12 or
24 h. Equal amounts of protein were separated by SDS-PAGE and immunoblotted with anti-IRS-1 antibody
(without IGF-I (top) or with IGF-I (middle)) or with anti--actin antibody (bottom). The bar graph is representa-
tive of three independent experiments. Error bars, mean  S.E. **, p  0.01.
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ditions on IGF-I actions, VSMCs overexpressing HA-tagged
IRS-1 (IRS-WT) were constructed. The basal total IRS-1 pro-
tein level was higher (5.2  0.1-fold, n  5, p  0.001) in
IRS-WT cells maintained in DMEM-HG compared with LacZ
control cells (Fig. 1C). Following exposure to IGF-I, IRS-1 was
reduced to a significantly greater extent in the LacZ cells (2.6
0.2-fold decrease) compared with a 1.9  0.1-fold decrease in
IRS-1 WT cells (n  3, p  0.01; Fig. 1D).
Effect of IRS-1 Overexpression on IGF-I-mediated SHPS-1
Phosphorylation, SHPS-1 Complex Assembly, Downstream Sig-
naling, and Cellular Proliferation—Cellular proliferation in
IRS-WT-overexpressing cells maintained in DMEM-HG was
significantly impaired (1.1  0.3-fold increase) compared with
LacZ control cells (1.98  0.1-fold increase) in response to
IGF-I (n  5, p  0.05; Fig. 2A). Similarly, VSMC migration in
response to IGF-I was significantly reduced (1.97  0.1-fold
reduction, n  4, p  0.05) in IRS-WT cells maintained in
DMEM-HG compared with LacZ control cells (Fig. 2B).
Because proliferation of VSMCs in high glucose has been
shown to be dependent on Shc phosphorylation and subse-
quent MAPK activation, we determined the Shc and MAPK
phosphorylation responses in SMCs overexpressing IRS-1 that
were maintained in DMEM-HG. The Shc phosphorylation
response to IGF-I was reduced 2.1 0.2-fold and 2.6 0.1-fold
at 5 and 10 min, respectively (n  4, p  0.01) in IRS-WT cells
compared with LacZ cells, and Shc-Grb2 binding was also
reduced 2.7  0.1-fold both at 5 and 10 min after IGF-I stimu-
lation (n  4, p  0.001) (Fig. 2C, top panels). Additionally,
phosphorylation of MAPK was found to be significantly atten-
uated (4.1  0.2-fold, n  5, p  0.01) in cells overexpressing
IRS-WT comparedwith LacZ cells in response to IGF-I after 10
min (Fig. 2C, bottom panels).
Phosphorylation of SHPS-1 and subsequent assembly of a
signaling complex is required for IGF-I stimulation of p52shc
phosphorylation andMAPK activation (2). SHP-2 is a key com-
ponent of that complex that binds directly to phosphorylated
SHPS-1 (33); hence, SHPS-1 phosphorylation and SHP-2
recruitment were evaluated. Phosphorylation of SHPS-1 was
found to be significantly impaired (5.1  0.2-fold reduction,
n  3, p  0.001) in IRS-WT cells compared with LacZ cells in
response to IGF-I (Fig. 2D). Similarly, the association of SHP-2
with SHPS-1was found to be reduced (4.2 0.1-fold,n 3, p
0.001) in IRS-WT cells comparedwith LacZ cells in response to
IGF-I (Fig. 2D). In contrast, the IGF-IR phosphorylation levels
remained the same in both IRS-WT cells and LacZ cells in
response to IGF-I (Fig. 2D). Taken together, the above data
demonstrate thatmaintenance of an IRS-1 level in SMCsmain-
tained in high glucose that was similar to the IRS-1 level in
VSMCs maintained in normal glucose was associated with a
reduction in several of the cellular responses to IGF-I, including
SHPS-1 phosphorylation, SHP-2 recruitment to SHPS-1, p52shc
phosphorylation, MAPK activation, and cell proliferation.
Effect of IGF-IR and IRS-1 on SHPS-1 Phosphorylation—
SHPS-1, a transmembrane protein, has been shown to be a sub-
strate of several tyrosine receptor kinases, including the insulin
receptor (37). Hence, we investigated whether IGF-IR kinase
could phosphorylate SHPS-1. In vitro phosphorylation assays
showed that IGF-I-activated IGF-IR directly phosphorylated
the SHPS-1/CD (18.7  2.2-fold, n  3, p  0.001) compared
with SHPS-1/CD without IGF-IR (Fig. 3A) or SHPS-1/CD with
inactivated IGF-IR (data not shown). Further, cells overex-
pressing IGF-IR maintained in HG conditions showed a 2.6 
0.1-fold increase in SHPS-1 phosphorylation compared with
LacZ cells in response to IGF-I (n 3, p 0.001; Fig. 3B).When
the IGF-IR inhibitor PQ401 was added in vitro, it inhibited
IGF-I receptor autophosphorylation (Fig. 3C, top). More
importantly, IGF-IR-mediated phosphorylation of SHPS-1/CD
was also inhibited (12.6  1.7-fold decrease, n  3, p  0.001;
Fig. 3C, second panel). Similarly, when VSMCs cultured in HG
conditions were treated with PQ401, IGF-IR phosphorylation
and SHPS-1 phosphorylation were decreased (1.7  0.2-fold
decrease, n  3, p  0.05) in response to IGF-I (Fig. 3D). Fur-
thermore, when IGF-I was used to stimulate IGF-IR phosphor-
ylation in VSMCs overexpressing IGF-IR (Fig. 3E, top) and the
IGF-IR immunoprecipitate was analyzed in vitro, SHPS-1/CD
phosphorylation was increased to a greater extent compared
with the non-IGF-I-stimulated IGF-IR immunoprecipitate
(9.1  0.2-fold increase, n  3, p  0.001; Fig. 3E, middle).
These cell-free in vitro and in vivo data demonstrate that
IGF-IR can directly phosphorylate SHPS-1/CD.
Because IRS-1 is a known substrate for both insulin receptor
and IGF-IR tyrosine kinases, we wished to determine whether
IRS-1 could compete with SHPS-1 as an IGF-IR substrate.
Recombinant IRS-1 was added to the in vitro phosphorylation
assays. Increasing concentrations of IRS-1 decreased the phos-
phorylation of SHPS-1/CD (3.9  0.3-fold decrease, n  3, p 
0.01) (Fig. 3F), but therewas no effect on IGF-IR autophosphor-
ylation. These observations, taken together with our results
showing that IRS-1-overexpressing cells exhibit impaired
SHPS-1 phosphorylation (Fig. 2D), suggest that IRS-1 is com-
peting with SHPS-1 for binding to IGF-IR, thereby altering
SHPS-1 phosphorylation.
Effect of Inhibition of IGF-IR/IRS-1 Association on SHPS-1
Phosphorylation—Previous studies have demonstrated that the
interaction between the NPXY motif (residues 947–950) of
IR/IGF-IR and the PTB domain of IRS-1 mediates its associa-
tion (7, 9). To determine whether disrupting IGF-IR/IRS-1
associationwould affect IGF-IR/SHPS-1 association and subse-
quent IGF-IR-mediated SHPS-1 phosphorylation, we used cell-
permeable peptides containing either the NPEY motif of
IGF-IR (peptide 299) or a peptide containing the amino acid
sequence between residues 206 and 217 of IRS-1 (peptide 301).
This sequence contains a region of the PTB domain that has
been proposed to mediate its binding to NPXY sequences.
IRS-WT cells exposed to either peptide 299 or peptide 301
showed decreased IGF-IR/IRS-1 association compared with
IRS-WT cells in response to IGF-I (2.3  0.1-fold, n  3, p 
0.001 for peptide 299; 1.7 0.2-fold, n 3, p 0.05 for peptide
301) (Fig. 4, A and B, top). IRS-1 tyrosine phosphorylation was
also significantly impaired (2.5  0.1-fold, n  3, p  0.001) in
response to IGF-I in IRS-WT cells exposed to peptide 301 com-
pared with non-exposed cells (supplemental Fig. 1B). The
reduction of IGF-IR/IRS-1 association was associated with an
increase in IGF-IR associationwith SHPS-1 (2.0 0.3-fold, n
3, p  0.05 for peptide 299; 2.6  0.2-fold, n  3, p  0.01 for
peptide 301). This resulted in a subsequent increase in SHPS-1
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FIGURE 2. IRS-1 overexpression impairs IGF-I-mediated SHPS-1 phosphorylation and subsequent SHPS-1 complex assembly, leading to reduction in
phosphorylation of MAPK and cellular proliferation. A, LacZ and IRS-WT cells were plated (3  104 cells) in DMEM-HG with 2% FBS prior to exposure to IGF-I in
DMEM-HG with 0.2% platelet-poor plasma. Forty-eight hours after the addition of IGF-I, the cell number was determined. **, p  0.01 when the change in cell number
in response to IGF-I in LacZ control cells is determined; *, p  0.05 when the number of cells proliferating after exposure to IGF-I is compared between LacZ and IRS-WT
cells. Error bars, meanS.E. B, LacZ and IRS-WT cells were grown in 6-well dishes in DMEM-HG containing 10% FBS. After wounding, they were allowed to migrate with
or without IGF-I in medium containing 0.2% FBS for 48 h. The total number of cells migrating past the wound line in the predetermined areas was counted. The results
shown are the meanS.E. of at least three independent experiments. **, p0.01 when the change in migrating cells in response to IGF-I in LacZ cells is compared with
LacZ cells without IGF-I; *, p  0.05 when the number of cells migrating in response to IGF-I is compared between LacZ and IRS-WT cells. C, confluent LacZ and IRS-WT
cells were serum-starved for 16 h in DMEM-HG and then exposed to IGF-I for the times indicated. The extent of Shc and IRS-1 phosphorylation was determined by
immunoprecipitating (IP) p52shc (first panel) or IRS-1 (fourth panel) and then immunoblotting (IB) with an anti-phosphotyrosine (Tyr(P)99 (PY99)) antibody. Similarly, the
lysates were immunoprecipitated with anti-Grb2 antibody, and the bottom portion of the blot was used for immunoblotting for p52shc (second panel), whereas the top
portion of the same blot was immunoblotted for IRS-1 (fifth panel). An equal amount of protein from cell lysates from the same experiment was used to immunoblot
for total Shc (third panel) and total IRS-1 (sixth panel). Similarly, an equal amount of protein from the same cell lysates was immunoblotted using anti-phospho-MAPK
(seventh panel). The blots were stripped and reprobed using anti--actin antibody (bottom panel). The bar graphs are representative of at least three independent
experiments and two independent transductions. Error bars, mean  S.E. ***, p  0.001 when the amount of Grb2 associated with Shc at 10 min in response to IGF-I
is compared between LacZ and IRS-WT cells; **, p  0.01 when the amount of phosphorylation of MAPK in response to IGF-I at 10 min is compared between LacZ and
IRS-WT cells. D, confluent LacZ- and IRS-WT-expressing cells were serum-starved for 16 h in DMEM-HG and then exposed to IGF-I for 5 min, and the extent of SHPS-1
phosphorylation and SHP-2 association was determined by immunoprecipitating with an anti-SHPS-1 antibody and immunoblotting with Tyr(P)99 (first panel) or with
anti-SHP-2 antibody (second panel). The extent of IGF-IR tyrosine phosphorylation was assessed by immunoprecipitating IGF-IR and immuoblotting for phosphoty-
rosine (fourth panel). Lysates from the same experiments were immunoblotted for total SHPS-1 (third panel) or for total IGF-IR (fifth panel). The bar graph shows the
relative increase in SHPS-1 phosphorylation for at least three independent experiments. Error bars, mean  S.E. ***, p  0.001 when increase in SHPS-1 phosphory-
lation in response to IGF-I is compared between LacZ- and IRS-WT-expressing cells.
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phosphorylation in IRS-WT cells exposed to either peptide
(3.1 0.2-fold, n 3, p 0.001 for peptide 299; 2.6 0.3-fold,
n  3, p  0.001 for peptide 301) compared with IRS-WT cells
not exposed to peptides in response to IGF-I (Fig. 4, A and B).
To control for potential differences in tyrosine phosphorylation
of peptide 299, the experiment was repeated using a tyrosine-
phosphorylated form. Following exposure to this peptide, the
amount of IRS-1 associated with IGF-IR and the tyrosine phos-
phorylation of IRS-1were significantly impaired (2.3 0.2- and
2.1  0.1-fold, respectively) in response to IGF-I after 5 min in
cells exposed to peptide compared
with non-exposed cells (n  3, p 
0.01). Further, the level of associa-
tion of SHPS-1 with IGF-IR and
SHPS-1 phosphorylationwas signif-
icantly increased in the cells
exposed to the peptide in response
to IGF-I at 5 min compared with
non-exposed cells (3.1  0.1- and
3.3  0.1-fold, respectively) (n  3,
p  0.001; supplemental Fig. 1A).
Formation of the SHPS-1 signal-
ing complex that leads to MAPK
pathway activation is dependent
upon SHP-2 recruitment to phos-
phorylated SHPS-1 (2). When we
determined the effect of peptide
301 on SHP-2 transfer, it failed to
restore the SHP-2 transfer to
SHPS-1 despite its ability to in-
crease SHPS-1 phosphorylation.
Furthermore, the amount of IRS-1
associated with SHP-2 in the pres-
ence of peptide 301 in response to
IGF-I was not reduced significantly
(1.0  0.1-fold, n  3, p  not sig-
nificant; Fig. 4B).
In order to confirm the findings
obtained in cells overexpressing
IRS-1, we used non-transfected
VSMCs cultured in DMEM-NG
(Fig. 1). When those cultures were
exposed to peptide 301, they
showed a significant reduction in
IGF-IR/IRS-1 association compared
with cells not exposed to the peptide
in response to IGF-I (3.6  0.1-fold,
n  3, p  0.001; Fig. 4C). This
reduction in IGF-IR/IRS-1 associa-
tion led to impairment of tyrosine
phosphorylation of IRS-1 in
response to IGF-I (2.0  0.2-fold)
compared with control cells. Pep-
tide exposure increased the SHPS-1
phosphorylation (2.2  0.3-fold)
and SHP-2 transfer to SHPS-1
(1.9 0.1-fold) in response to IGF-I
(n  3, p  0.05; Fig. 4C). Further-
more, a significant increase was observed in IGF-IR/SHPS-1
association (2.2  0.2-fold, n  3, p  0.01), Shc tyrosine phos-
phorylation (1.9  0.1-fold, n  3, p  0.05), and phosphory-
lation of MAPK (1.9  0.1-fold, n  3, p  0.05;
supplemental Fig. 1C) in cells exposed to peptide 301 in
response to IGF-I compared with non-exposed cells. Concom-
itant incubation of VSMCs maintained in DMEM-NG with
peptide 301 increased cellular proliferation in response to IGF-I
(1.8  0.1-fold, n  3, p  0.01; supplemental Fig. 1D). Taken
together, these results suggest that IRS-1 and SHPS-1 compete
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for binding to IGF-IR kinase and that the level of IRS-1 that is
present in VSMCsmaintained in normal glucose is sufficient to
suppress SHPS-1 phosphorylation and the subsequent assem-
bly of the SHPS-1-associated signaling complex.
Effect of SHP-2 Sequestration by IRS-1 on SHPS-1 Complex
Assembly—IRS-1 contains several YXX(L/I/V) motifs that are
known to bind to SHP-2 following stimulation of IRS-1 tyrosine
phosphorylation. Therefore, we proposed that IRS-1 overex-
pression resulted in sequestration of SHP-2 and prevented its
recruitment to phosphorylated SHPS-1 (Fig. 4B). To test this
hypothesis, we prepared a HA-tagged IRS-1 mutant (IRS-FF),
wherein tyrosine residues 1179 and 1229 were mutated to phe-
nylalanine (Fig. 5A). The association of IRS-1 and SHP-2 was
reduced 2.7  0.1-fold in the IRS-FF mutant (n  5, p  0.01)
compared with IRS-WT cells in response to IGF-I after 5 min
(Fig. 5B). Recent studies have shown that IRS-1 binding to
SHP-2 could potentially be mediated by five other sites, Tyr759,
Tyr760, Tyr891, Tyr935, and Tyr1006 (38). This could explain the
residual IRS-1 binding to SHP-2 that is detected using the
IRS-FF mutant. Despite the reduction in SHP-2 binding to
IRS-1, the amount of SHP-2 transferred to SHPS-1 was still
impaired in IRS-FFmutant cells in response to IGF-I compared
with LacZ cells. This is probably due to the fact that SHPS-1
phosphorylation was still significantly impaired in the IRS-FF
cells compared with LacZ cells (Fig. 5C). Furthermore, the lev-
els of SHPS-1 phosphorylation and SHP-2 transfer failed to
increase significantly in the IRS-FF cells compared with
IRS-WT cells in response to IGF-I.
To determine why inhibiting SHP-2 association with IRS-1
did not alter SHP-2 binding to SHPS-1, we assessed IRS-1/
IGF-IR association using the cells that were overexpressing the
IRS-FF mutant. When those cells were compared with the
IRS-WT cells, there was no difference in IRS-1/IGF-IR associ-
ation in response to IGF-I after 5min (1.1 0.1-fold, n 3, p
not significant; Fig. 5C). The difference in IGF-IR/IRS-1 asso-
ciation after 10 min of IGF-I stimulation could be explained by
the ability of SHP-2 to dephosphorylate IRS-1 in WT cells and
not in FF mutant cells (data not shown). To determine if inhib-
iting IGF-IR/IRS-1 interaction by incubating the blocking pep-
tide with the IRS-FF mutant cells could rescue the SHPS-1
phosphorylation and SHP-2 recruitment to SHPS-1, cells
expressing the IRS-1-FF mutant were exposed to peptide 301.
The addition of peptide 301 resulted in increased IGF-IR asso-
ciation with SHPS-1 in response to IGF-I compared with cells
not exposed to the peptide (2.2  0.1-fold, n  5, p  0.05; Fig.
5D). Similarly, there was an increase in SHPS-1 phosphoryla-
tion (2.6  0.1-fold, n  3, p  0.001) and the subsequent
SHPS-1/SHP-2 association (2.3  0.3-fold, n 3, p 0.05; Fig.
5D). More importantly, tyrosine phosphorylation of p52shcwas
significantly increased in the IRS-FF cells exposed to peptide
301 (2.9  0.2-fold, n  3, p  0.001) compared with cells not
exposed to the peptide in response to IGF-I (Fig. 5D). Taken
together, these results suggest that disruption of association
IGF-IR/IRS-1 association and inhibition of SHP-2 binding to
IRS-1 appears to be required for optimal SHP-2 transfer to
SHPS-1 and Shc activation.
Expression of an IRS-1 Double Mutant That Impairs IGF-IR/
IRS-1 Association and IRS-1/SHP-2 Association Restores SHPS-1
Phosphorylation and SHP-2 Association with SHPS-1—To defin-
itively prove that IRS-1 binding to both IGF-IR and SHP-2
accounted for inhibition of SHPS-1 phosphorylation and
downstream signaling, we used the IRS-FF mutant as a tem-
plate andmutated the arginine residues 212, 213, and 217 in the
IRS-1 PTB domain to glutamine because these residues have
been shown to mediate IRS-1 association with IR/IGF-IR (7,
10). The combinedmutant is termed IRS-R3Q-FF. The expres-
sions of HA-tagged IRS-WT and IRS-R3Q-FF were found to be
similarwhen the cell lysateswere compared (Fig. 6A). As shown
in Fig. 6B, this IRS-1mutant had significantly impaired binding
to IGF-IR in response to IGF-I compared with cells expressing
IRS-WT. Further, the tyrosine phosphorylation of IRS-1 and
the subsequent IRS-1 binding to Grb2 was found to be signifi-
cantly reduced in IRS-R3Q-FF compared with IRS-WT cells in
response to IGF-I (3.3  0.1-fold, n  3, p  0.001). The
amount of SHP-2 bound to IRS-1 was found to be reduced
(1.9 0.2-fold, n 3, p 0.05) but not completely abolished in
FIGURE 3. IGF-IR kinase phosphorylates SHPS-1 and IRS-1 binding to IGF-IR impairs its ability to phosphorylate SHPS-1 in cells and in a cell-free
system. A, SHPS-1/CD generated by in vitro translation using wheat germ extract was incubated in vitro (denoted by the plus or minus sign) with or without
activated IGF-IR kinase as described under “Materials and Methods.” The supernatant was analyzed by immunoblotting (IB) for phosphotyrosine (top) or SHPS-1
(bottom). The relative -fold increase in the phosphorylation of SHPS-1/CD is shown in the bar graph. Error bars, mean  S.E. ***, p  0.001. B, confluent LacZ and
IGF-IR-WT cells were serum-starved for 16 h in DMEM-HG and exposed to IGF-I for 5 min. The extent of SHPS-1 phosphorylation was determined by immuno-
precipitating (IP) SHPS-1 and immunoblotting with Tyr(P)99 (first panel). Lysates from the same experiments were immunoblotted for total SHPS-1 (second
panel). C, in similar experiments, additional samples that contained IGF-IR and SHPS-1/CD were exposed to the IGF-IR tyrosine kinase inhibitor, PQ401 15 M
(lane 3) or 50 M (lane 5), and vehicle control (DMSO) was added to lanes 2 and 4. Half of the supernatant was analyzed by immunoblotting using Tyr(P)99 (PY99)
antibody representing IGF-IR phosphorylation (top) and SHPS-1/CD phosphorylation (bottom). Both bands were identified by electrophoretic mobility. The
other half of the supernatant was analyzed by immunoblotting for total IGF-IR and total SHPS-1 (lower panels). The relative -fold increase in the SHPS-1/CD
phosphorylation and suppression by the inhibitor is shown in the bar graph. Error bars, mean  S.E. ***, p  0.001. D, VSMCs cultured and maintained in
DMEM-HG were serum-starved and then incubated with or without PQ401 (50 M) for 1 h. IGF-I was added for 5 min. Cell lysates were immunoprecipitated with
anti-IGF-IR antibody (first panel) or with anti-SHPS-1 antibody (second panel) and immunoblotted for Tyr(P)99. Cell lysates were immunoblotted with anti-IGF-IR
(third panel) or anti-SHPS-1 antibody (fourth panel). E, confluent IGF-IR-overexpressing cells were serum-starved for 16 h in DMEM-HG and then exposed to IGF-I
for the times indicated. The cell lysates were immunoprecipitated with anti-IGF-IR antiserum. Some aliquots of reconstituted immunoprecipitate were incu-
bated with SHPS-1/CD in in vitro phosphorylation assays (lanes 1–3) or with buffer alone (Con). After centrifugation, the resultant supernatants were immuno-
blotted using a phosphotyrosine antibody IGF-IR (top) or phospho-SHPS-1/CD (middle). Similar lysates were immunoprecipitated and immunoblotted with
anti-IGF-IR antibody as a loading control (bottom). To ascertain the specificity of the bands, an antibody only control was also used. The bar graph represents the
relative increase in SHPS-1/CD phosphorylation in response to IGF-I at 10 min compared with non-stimulated immunoprecipitates; ***, p  0.001 based on at least
three independent experiments. Error bars, mean  S.E. F, in an in vitro assay, the SHPS-1/CD and activated IGF-IR were incubated with increasing concentrations of
recombinant full-length IRS-1, 20 ng (lane 3) and 40 ng (lane 4), for 30 min. An aliquot of each supernatant was analyzed by immunoblotting with an anti-phospho-
tyrosine antibody that recognizes IGF-IR tyrosine phosphorylation (top) or SHPS-1/CD (middle). The third panel indicates the total SHPS-1/CD. The -fold increase in
SHPS-1/CD phosphorylation in response to IGF-IR is shown in the bar graph. Error bars, mean  S.E. ***, p  0.001. The -fold decrease in SHPS-1 phosphorylation in the
presence of 40 ng of IRS-1 (lane 4) is shown (bar graph) in comparison with no IRS-1 addition (lane 2). Error bars, mean  S.E.; **, p  0.01.
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FIGURE 4. Inhibition of IRS-1 binding to IGF-IR increases association of SHPS-1 with IGF-IR and increases SHPS-1 phosphorylation. A and B, confluent
cultures expressing WT-IRS-1 were serum-starved overnight and then incubated with or without cell-permeable peptides, IGF-IR (peptide 299) (A) or IRS-1
(peptide 301) (B) at 20 g/ml for 2 h. IGF-I was added for either 5 or 10 min. Cell lysates were immunoprecipitated (IP) with anti-IGF-IR antibody and then
immunoblotted for IRS-1 (top panel) or for SHPS-1 (second panel). The blots were stripped and reprobed with anti-IGF-IR antibody (third panel). Cell lysates from
the same experiments were immunoprecipitated with anti-SHPS-1 antibody and immunoblotted with Tyr(P)99 antibody (fourth panel). The blots were stripped
and reprobed with anti-SHPS-1 antibody (fifth panel). B, in addition, cell lysates were immunoprecipitated with anti-SHPS-1 antibody and immunoblotted for
SHP-2 (sixth panel). Similar lysates were immunoprecipitated with anti-SHP-2 antibody and immunoblotted for IRS-1 (seventh panel) or SHP-2 (eighth panel). The
top bar graph shows the relative increase in IGF-IR/SHPS-1 association for at least three independent experiments. Error bars, mean  S.E. *, p  0.05 when
increase in IGF-IR/SHPS-1 association in response to IGF-I at 10 min is compared between IRS-WT cells with and without peptide 299. The middle bar graph
shows the relative increase in SHPS-1 phosphorylation for at least three independent experiments. Error bars, mean  S.E. ***, p  0.001 when increase in
SHPS-1 phosphorylation in response to IGF-I after 10 min is compared in IRS-WT-expressing cells with or without peptide 301. C, VSMCs cultured and
maintained in DMEM-NG were serum-starved and then incubated with or without cell-permeable IGF-IR/IRS-1 peptide 301 at a concentration of 5 g/ml for 2 h.
IGF-I was added for 5 min with and without the peptide. Cell lysates from the above experiments were immunoprecipitated with anti-IRS-1 antibody and
immunoblotted for either IGF-IR (upper panel) or Tyr(P)99 (second panel). The blots were stripped and reprobed with anti-IRS-1 antibody (third panel). Cell lysates
from the same experiments were immunoprecipitated with anti-SHPS-1 antibody and immunoblotted with Tyr(P)99 antibody (fourth panel) or with anti-SHP-2
antibody (fifth panel). The blots were stripped and reprobed with anti-SHPS-1 antibody (sixth panel). The bar graph shows the relative increase in SHPS-1
phosphorylation for at least three independent experiments. Error bars, mean  S.E. **, p  0.01 when the increase in SHPS-1 phosphorylation in response to
IGF-I is compared with or without peptide 301.
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the double mutant compared with IRS-WT cells (Fig. 6B). Fur-
thermore, following IGF-I stimulation, there was a significant
increase in SHPS-1 binding to IGF-IR (2.9 0.4-fold,n 3, p
0.01) and an increase in SHPS-1 phosphorylation (3.3  0.1-
fold, n  3, p  0.001) in the cells expressing the IRS-R3Q-FF
mutant cells compared with IRS-WT cells (Fig. 6C). The sub-
sequent transfer of SHP-2 to SHPS-1 was also increased in IRS-
R3Q-FF mutant cells compared with IRS-WT cells in response
to IGF-I (2.1  0.2-fold, n  3, p  0.01; Fig. 6C). When the
IRS-R3Q-FF cells were analyzed, p52shc phosphorylation was
found to be increased in response to IGF-I compared with
IRS-WTcells (3.0 0.2-fold,n 3, p 0.001). Cells expressing
IRS-R3Q-FF cells showed increased phosphorylation ofMAPK
(3.3  0.2-fold, n  3, p  0.01) compared with cells overex-
pressing IRS-WT in response to IGF-I (Fig. 6C). Using a lower
degree of cellular confluence and increased IGF-I concentra-
tion, we observed a decrease in basal Shc phosphorylation
response in the mutant cells. Further, in response to IGF-I, the
phosphorylation of MAPK increased significantly (3.9  0.1,
n  3, p  0.001) in the IRS-R3Q-FF cells (supplemental
Fig. 2). The proliferation response of cells expressing IRS-
R3Q-FF to IGF-I was found to be significantly greater (2.1 
0.3-fold, n  4, p  0.01) compared with cells expressing
IRS-WT (Fig. 6D). These results demonstrate that inhibiting
IRS-1 binding to IGF-IR and to SHP-2 attenuated IRS-1 tyro-
sine phosphorylation and Grb2 binding. Furthermore, these
changes resulted in increased SHPS-1 association with IGF-IR
kinase, SHPS-1 phosphorylation, SHP-2 transfer, phosphory-
lation of Shc and MAPK, and cellular proliferation in response
to IGF-I.
Effect of IRS-1 Silencing on SHPS-1 Phosphorylation—To fur-
ther evaluate the role of IRS-1 in SHPS-1 phosphorylation, we
silenced IRS-1 using short hairpin RNA. VSMCs expressing
IRS-1 short hairpin RNA showed a 89  1% decrease in IRS-1
(supplemental Fig. 3A) compared with empty vector control.
The basal SHPS-1 phosphorylation was significantly increased
(4.1 0.2-fold, n 3, p 0.01) in IRS-1 Si cells compared with
EVC cells, and IGF-I induced an additional SHPS-1 phosphor-
ylation (1.9  0.2-fold, n  3, p  0.05) after 5 min
(supplemental Fig. 3B). This basal SHPS-1 phosphorylationwas
due to a basal increase in IGF-IR/SHPS-1 association (2.3 
0.2-fold) and an additional (2.4 0.1-fold) increase in response
to IGF-I in IRS-1 Si cells compared with EVC. Furthermore, a
1.9  0.1-fold increase in basal MAPK phosphorylation and an
additional 2.1  0.2-fold increase in response to IGF-I was
observed in IRS-1 Si cells compared with EVC. In addition,
cellular proliferation was basally increased in IRS-1 Si cells
compared with EVC (1.4  0.2-fold), and it increased an addi-
tional 1.7  0.3-fold in response to IGF-I (n  3, p  0.01;
supplemental Fig. 3C). In addition to increased IGF-IR/SHPS-1
association, the increase in basal SHPS-1 phosphorylation was
probably due to an increase in basal IGF-IR phosphorylation
(3.9  0.2-fold, n  2) in the IRS-1 Si cells (supplemental
Fig. 3B), which would allow more activated IGF-IR kinase to
bind and phosphorylate SHPS-1.
DISCUSSION
IRS-1 is a major substrate for IGF-IR (4, 9) and has been
shown to mediate several signaling events, including activation
of both the phosphatidylinositol 3-kinase and MAPK signaling
pathways (4, 9, 39, 40). Previously, we showed that IGF-I-stim-
FIGURE 5. IRS-1 sequesters SHP-2 and impairs its transfer to SHPS-1.
A, VSMCs overexpressing IRS-WT and the IRS-FF mutant were serum-starved
overnight and analyzed for recombinant protein expression. Cell lysates were
immunoblotted (IB) for HA (top) and for -actin (bottom). B, confluent cultures
of IRS-WT and IRS-FF cells were serum-starved for 16 h and then exposed to
IGF-I for the times indicated. Cell lysates were immunoprecipitated (IP) with
anti-HA and immunoblotted for SHP-2 (top). The membranes were stripped
and probed with anti-HA antibody (bottom). C, confluent cultures of control
LacZ cells, IRS-WT cells, and IRS-FF cells were serum-starved overnight and
stimulated with IGF-I for 5 or 10 min. The cell lysates were immunoprecipi-
tated with anti-SHPS-1 and immunoblotted for Tyr(P)99 (top panel) or SHP-2
(second panel). They were stripped and reprobed with anti-SHPS-1 antibody
(third panel). Lysates from similar experiments were immunoprecipitated
with anti-IGF-IR and immunoblotted for IRS-1 (fourth panel). The blots were
stripped and reprobed for IGF-IR (bottom panel). D, confluent IRS-FF cell cul-
tures were serum-starved for 14 –16 h and incubated with or without cell-
permeable IGF-IR/IRS-1 peptide 301 (20 g/ml) for 2 h followed by IGF-I for
either 5 or 10 min. Cell lysates were immunoprecipitated with anti-SHPS-1
and immunoblotted for IGF-IR (first panel), Tyr(P)99 (second panel), SHP-2 (third
panel), or SHPS-1 (fourth panel). Lysates were immunoprecipitated with
Tyr(P)99 (PY99) and immunoblotted with anti-p52shc (fifth panel) or immuno-
blotted directly for total Shc (bottom panel). The bar graph shows the relative
increase in Shc phosphorylation for at least three independent experiments.
Error bars, mean  S.E. **, p  0.01 when increase in Shc phosphorylation in
response to IGF-I is compared between IRS-FF mutant cells with or without
peptide 301.
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FIGURE 6. Inhibition of IRS-1 binding to both IGF-IR and SHP-2 restores SHPS-1 phosphorylation and SHPS-1 complex assembly and enhances the
cellular proliferation response to IGF-I. A, VSMCs expressing IRS-WT and the IRS-R3Q-FF mutant were serum-starved overnight and analyzed for recombi-
nant protein expression. Cell lysates were immunoblotted (IB) for HA (top) or -actin (bottom). B, confluent cultures of IRS-WT and IRS-R3Q-FF cells were
serum-starved and then exposed to IGF-I for the indicated time periods. Cell lysates were immunoprecipitated (IP) with anti-HA and immunoblotted for IGF-IR
(top panel), Tyr(P)99 (PY99; second panel), SHP-2 (third panel), or total HA (fourth panel). Cell lysates from similar experiments were immunoprecipitated with
Grb2 and immunoblotted for IRS-1 (fifth panel) or total Grb2 (sixth panel). The bar graphs are representative of at least three independent experiments. Error
bars, mean  S.E. ***, p  0.001 when the amount of Grb2 associated with IRS-1 at 5 min in response to IGF-I is compared between IRS-WT and IRS-R3Q-FF cells.
C, the cell lysates from the above experiments and similar experiments were immunoprecipitated with anti-SHPS-1 antibody and immunoblotted for IGF-IR
(top panel), phosphotyrosine (second panel), SHP-2 (third panel), or total SHPS-1 (fourth panel). Similarly, lysates were immunoprecipitated with Tyr(P)99
antibody and immunoblotted for p52shc (fifth panel). Similar lysates were immunoprecipitated with anti-Grb2 and immunoblotted for Shc (sixth panel) or Grb2
(seventh panel). Ten micrograms of protein from the same cell lysates was immunoblotted directly for phospho-MAPK (eighth panel) or -actin (bottom panel).
The bar graphs are representative of at least three independent experiments. Error bars, mean  S.E. **, p  0.01 when the amount of Grb2 associated with Shc
(middle graph) or amount of phosphorylation of MAPK (bottom graph) at 10 min in response to IGF-I is compared between IRS-WT and IRS-R3Q-FF cells.
D, IRS-WT and IRS-R3Q-FF cells were plated (3  104 cells) in DMEM-HG with 2% FBS prior to exposure to IGF-I in DMEM-HG with 0.2% platelet-poor plasma.
Forty-eight hours after the addition of IGF-I, cell number was determined. **, p  0.01 when the change in number of cells proliferating in response to IGF-I is
compared between IRS-WT and IRS-R3Q-FF cells. Error bars, mean  S.E.
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ulated IRS-1 phosphorylation and subsequent Grb2 binding
were markedly down-regulated in VSMCs that had been main-
tained in high glucose (e.g. 25 mM) (29). The results from the
current study confirm the previous observation that VSMCs in
high glucose had a significant reduction in total IRS-1 protein
levels at 12, 24, and 48 h comparedwith cells exposed to normal
glucose. Exposure to high glucose has been shown to decrease
IRS-1 levels in a variety of cell types (32, 41). IRS-1 degradation
has been extensively studied in insulin-sensitive cell types, such
as adipocytes and skeletal muscle cells and also in these tissues
in animal models (13, 31, 42–44). Hyperglycemia-induced
IRS-1 down-regulation has been shown in vascular smooth
muscle followingPKCactivation (45),-adrenergic stimulation
(46), and angiotensin II exposure (47, 48). Exposure to growth
factors, including IGF-I, also enhances IRS-1 degradation in a
variety of cells (25, 26, 49, 50). In the present study, exposure to
high glucose and IGF-I for 24 or 48 h reduced the IRS-1 levels
significantly compared with cells maintained in high glucose
alone. This observation is supported by the previous studies
that showed that the combination of high glucose and insulin
reduced IRS-1 levels in several model systems and in humans
with type 2 diabetes and obesity (30, 31, 51, 52). Furthermore, in
the current study, IRS-1 tyrosine phosphorylation and Grb2
binding were impaired in response to IGF-I, suggesting that
exposure to high glucose with subsequent IRS-1 down-regula-
tion attenuates IRS-1-mediated signaling.
In an attempt to determine the consequences of the failure to
down-regulate IRS-1, we transduced VSMCs with an IRS-1
cDNA andmaintained them in 25mM glucose. Maintenance of
this increased IRS-1 level led to impaired IGF-I stimulated
SHPS-1 phosphorylation, but it had no effect on IGF-I-stimu-
lated IGF-I receptor phosphorylation. That this effect is direct
is supported by our observation that IRS-1 inhibited IGF-IR-
mediated SHPS-1 phosphorylation in vitro in a concentration-
dependent manner. In VSMCs exposed to high glucose, IGF-I
induces SHPS-1 phosphorylation
(53). SHPS-1 has been demon-
strated to be a substrate of various
growth factor receptor tyrosine
kinases, including the insulin and
IGF-I receptor (19, 37, 54–58). The
role of IRS-1 in inhibiting SHPS-1
phosphorylation in intact SMCswas
confirmed by using three indepen-
dent methods. First, in SMCs main-
tained in normal glucose, SHPS-1
phosphorylation was suppressed,
and the addition of a synthetic pep-
tide that inhibited IGF-IR/IRS-1
association enhanced SHPS-1 phos-
phorylation. Second, the addition of
two synthetic peptides that dis-
rupted IRS-1/IGF-IR association to
cells maintained in hyperglycemia
that were overexpressing IRS-1 led
to enhanced SHPS-1 phosphoryla-
tion. Third, expression of a mutant
form of IRS-1 that could not bind to
IGF-IR at levels that were comparable with WT IRS-1 expres-
sion also led to enhanced IGF-I-stimulated SHPS-1 phosphor-
ylation. These findings support the conclusion that IRS-1 func-
tions by binding directly to the IGF-I receptor and suppressing
IGF-I receptor-mediated SHPS-1 phosphorylation.
Crystal structure and mutational analysis of the IRS-1 PTB
domain showed that arginines 212, 213, and 217 are respon-
sible for binding to the NPXY motif in the receptor, and
substitution with glutamine resulted in a complete loss of
binding (7, 10). Our findings confirm the importance of
these residues because the mutation of the three arginine
residues in the PTB domain of the IRS-1 significantly
impaired IRS-1/IGF-IR association and IRS-1 tyrosine phos-
phorylation following IGF-I stimulation. That IRS-1/IGF-IR
association was not completely inhibited can be explained by
the fact that IRS-1 also binds to the major autophosphory-
lation sites (Tyr1131, Tyr1135, and Tyr1136) of the IGF-IR (9).
In addition, inhibition of IGF-IR/IRS-1 by both phosphory-
lated and non-phosphorylated forms of peptide 299 suggests
that both peptides compete with intact IGF-IR for binding to
IRS-1 and supports the conclusion that IRS-1/IGF-IR asso-
ciation is occurring through this interaction.
Following phosphorylation of YXX(L/I/V) motifs within
the SHPS-1 cytoplasmic domain, SHP-2 is recruited to
SHPS-1, and this is essential for optimal phosphorylation
of Shc and MAPK activation in response to IGF-I (2). Our
study shows that in addition to inhibiting IGF-IR-mediated
SHPS-1 phosphorylation, IRS-1 also sequesters SHP-2, lim-
iting its translocation toSHPS-1 followingSHPS-1phosphor-
ylation. IRS-1 also contains seven YXX(L/I/V) motifs that
could bind to the SHP-2 Src homology 2 domains, and sub-
stitution of IRS-1 Tyr1172 and Tyr1222 to phenylalanine has
been shown to reduce SHP-2/IRS-1 association (59, 60). In
this study, we used several approaches to show that IRS-1 func-
tions in part by sequestering SHP-2 and preventing its recruit-
FIGURE 7. Proposed role of IRS-1 in regulating SHPS-1 phosphorylation under hyperglycemic conditions.
A, in VSMCs under normal glucose conditions, in response to IGF-I, competitive binding of IRS-1 to IGF-IR
impairs the access of SHPS-1 to IGF-I receptor kinase, thereby decreasing SHPS-1 phosphorylation. Further,
IRS-1 sequesters SHP-2, leading to impaired assembly of the signaling complex on SHPS-1. B, in high glucose
conditions, reduction in IRS-1 levels allows SHPS-1 improved access to the IGF-I receptor kinase, leading to
enhanced phosphorylation of SHPS-1 and subsequent SHP-2 transfer. This facilitates formation of the SHP-
2SrcShcGrb-2 signaling complex, which augments phosphatidylinositol 3-kinase and MAPK pathway activa-
tion. C, overexpression of IRS-1 decreases SHPS-1 access to the IGF-IR kinase, SHPS-1 phosphorylation, and
subsequent complex assembly. The IRS-1 double mutant with impaired binding to IGF-IR and SHP-2 allows
increased SHPS-1 access to IGF-IR kinase, thus increasing SHPS-1 phosphorylation and SHP-2 transfer, thereby
leading to increased phosphorylation of MAPK and cellular proliferation in response to IGF-I.
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ment to SHPS-1. First, the cells expressing the IRS-1 Y1179F/
Y1229F substitution mutant had decreased IRS-1/SHP-2
binding in response to IGF-I. Additionally, exposure of IRS1-FF
mutant cells to a peptide that inhibited IRS-1 association with
IGF-IR increased SHPS-1 phosphorylation and restored the
subsequent SHP-2 transfer. Second, expression of a combined
mutant (IRS-R3Q-FF) in which both IRS-1/IGF-IR and IRS-1/
SHP-2 bindingwere decreased led to increases in SHPS-1 phos-
phorylation and subsequent SHP-2 transfer to SHPS-1. Previ-
ous studies have shown that IRS-1/SHP-2 association is
differentially regulated in different tissues (61), in response to
changes in glucose (62) and state of SMC differentiation (63).
These findings suggest that this could be an important mecha-
nism for regulating cellular responsiveness to IGF-I.
In VSMCs, Shc phosphorylation in response to IGF-I
depends on SHPS-1 phosphorylation and subsequent SHPS-1
complex assembly (2, 29). Although some studies have shown
that IRS-1 and Shc are competitive substrates for receptor tyro-
sine kinase (8, 9, 64), our results show that competition occurs
between SHPS-1 and IRS-1, and this leads to impaired SHPS-1
phosphorylation. Further, IGF-IR overexpression increased
SHPS-1 phosphorylation in response to IGF-I. Therefore,
attenuation of Shc phosphorylation is not due to direct Shc/
IRS-1 competition for access to IGF-IR. Shc has been shown to
co-immunoprecipitate with several activated tyrosine kinase
receptors, such as epidermal growth factor receptors, erbB-2/
neu, and Trk (21, 65–67); however, it does not co-immunopre-
cipitate with activated IR (68, 69). Therefore, the activation of
Shc in VSMCs in response to IGF-I is regulated by SHP-2Src
transfer to SHPS-1 and Src activation (2, 20).
These observations raise the question of the role of IRS-1 in
VSMCs maintained in normoglycemic conditions. Our prior
studies have shown that when IRS-1 levels are substantially
increased (e.g. VSMCs maintained in 5 mM glucose), SHPS-1
phosphorylation, SHP-2 transfer, and Shc/MAPK activation
are suppressed (29, 70). Consequently, although the protein syn-
thesis response to IGF-I ismaintained, the cellmigration and pro-
liferation responses are significantly decreased. Our finding that
inhibition of IGF-IR/IRS-1 association in VSMCsmaintained in 5
mM glucose resulted in significant enhancement of SHPS-1 phos-
phorylation suggests that this mechanism is operative in VSMCs
exposed to normal glucose. This observation could have major
physiologic significance formaintenance of normal vascular func-
tion. Innormalmice,VSMCsaremaintained in thequiescent state
(71, 72) andhave aminimal proliferative response to IGF-I admin-
istration. In contrast, the presence of diabetes cell proliferation is
increased substantially (70). Because differentiated VSMCs in
blood vessels are maintained in a non-proliferative state, expres-
sion of IRS-1maybe one of the important determinants that allow
normal protein synthesis andhypertrophic responses to IGF-I and
insulinwhile functioning simultaneously to inhibit cell replication.
In contrast, transition to the dedifferentiated phenotype could
possibly require a major decrease in IRS-1 in order to permit
MAPK pathway activation (17, 73). This conclusion is supported
by the results of this study,wherein IRS-1 silencing increasedbasal
IGF-IR phosphorylation, which in turn, in the absence of IRS-1
binding, had increased access to SHPS-1, thereby augmenting
basal SHPS-1 phosphorylation. Future studies should investigate
the role of IRS-1 in animal models and determine if IRS-1 is regu-
lating themitogenic response to IGF-I in vascular tissue in vivo.
In summary, exposure of VSMCs to high glucose and IGF-I
results in down-regulation of IRS-1, thus allowing IGF-I-stim-
ulated SHPS-1 phosphorylation and SHPS-1 complex assem-
bly. The mechanism by which IRS-1 functions is due to its abil-
ity to bind to IGF-IR and inhibit IGF-IR mediated SHPS-1
tyrosine phosphorylation as well as sequestration of SHP-2,
which inhibits the assembly of the signaling complex on
SHPS-1. These changes result in inhibition of IGF-I-stimulated
increases in MAPK activation and cell proliferation (Fig. 7).
Taken together with the findings from our previous studies,
these results have significant implications for understanding
the role of IGF-I in stimulating the proliferation of neointimal
VSMCs that have been exposed to hyperglycemic stress.
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